Drug intelligence / Profile preview

VB-001

Development stage: Preclinical
Lead developer: VST Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

VB-001 is a clinical-stage biopharmaceutical drug being developed for the treatment of atopic dermatitis. It was part of the pipeline of Vyome Therapeutics, an Indian biopharmaceutical company focused on dermatology, which merged with ReShape Lifesciences. The drug's specific mechanism of action and modality are not detailed in the provided context.

Other names: humanized monoclonal antibody targeting Syndecan-2

Targets

SDC2 (Syndecan-2)

Beyond the preview

Go deeper on VB-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB-001.

Explore the full profile